School of Medicine


Showing 1-50 of 66 Results

  • Andrei Iagaru

    Andrei Iagaru

    Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center

    Current Research and Scholarly Interests Current research projects include:
    1) PET/MRI and PET/CT for Early Cancer Detection
    2) Targeted Radionuclide Therapy
    3) Clinical Translation of Novel PET Radiopharmaceuticals;

  • David Iberri

    David Iberri

    Clinical Assistant Professor, Medicine - Hematology

    Bio Dr. Iberri is a medical oncologist and hematologist who specializes in the treatment of hematologic malignancies. His clinical practices runs the gamut of malignant and non-malignant hematologic disorders including acute and chronic leukemias, multiple myeloma and lymphomas, and bleeding and thrombotic disorders. He is actively involved in clinical trials evaluating novel agents in hematologic malignancies. His research interests are in the development and application of biomarkers to select patients most likely to benefit from therapy.

  • Kenzo Ichimura

    Kenzo Ichimura

    Postdoctoral Research Fellow, Pulmonary and Critical Care Medicine

    Bio My long-term goal as a physician-scientist is to develop therapeutic strategies for right heart failure by elucidating its pathophysiology.

    I graduated from Kyushu University, School of Medicine in Fukuoka, Japan in 2008. Following a residency program at Aso Iizuka Hospital, I finished fellowship in Emergency Medicine (1 year) and Cardiovascular Medicine (2 years). My clinical expertise is general cardiology, cardiac catheterization, echocardiography, and cardiac critical care.

    After my clinical training, I started my research career working towards a Ph.D. under the mentorship of Dr. Kensuke Egashira. During my Ph.D., I published two papers focusing on the development of novel therapeutics for acute myocardial infarction and pulmonary arterial hypertension. Through this research experience, I developed skills in modeling and assessing cardiovascular disease in both small (rodents) and large animals (pigs)

    In 2017, I was appointed as an Assistant Professor and attending physician in the Department of Emergency and Critical Care Medicine at Kyushu University Hospital. During this period, I learned that right heart failure was one of the most devastating conditions with no treatment options in patients with pulmonary hypertension, congenital heart disease, and patients on long-term mechanical ventricular assist devices. I also continued my research with a research grant funded by the Japanese Society for the Promotion of Science.

    In 2019, I decided to further expand my research field into right heart failure and joined Dr. Edda Spiekerkoetter?s at Stanford University as a postdoctoral fellow. I am currently focusing on the role of BMPR2 in the cardiomyocytes, the structural changes in the right ventricle under pressure overload, and the development of right ventricle-targeting therapy in pulmonary hypertension.

  • Ibrahim Adejoh Idakoji

    Ibrahim Adejoh Idakoji

    Clinical Assistant Professor, Radiology

    Bio Ibrahim Idakoji is a native of the Bay Area and practicing Interventional Radiologist at Stanford Medical Center who specializes in minimally invasive, image-guided percutaneous and endovascular procedures that aid in the diagnosis and treatment of complex vascular and oncologic disease. Some of his areas of interest include: treatment of both acute and chronic venous thromboembolic disease, treatment of primary and metastatic hepatic malignancy, and percutaneous pain management.

  • Juliana Idoyaga

    Juliana Idoyaga

    Assistant Professor of Microbiology and Immunology

    Current Research and Scholarly Interests The Idoyaga Lab is focused on the function and biology of dendritic cells, which are specialized antigen-presenting cells that initiate and modulate our body?s immune responses. Considering their importance in orchestrating the quality and quantity of immune responses, dendritic cells are an indisputable target for vaccines and therapies.

    Dendritic cells are not one cell type, but a network of cells comprised of many subsets or subpopulations with distinct developmental pathways and tissue localization. It is becoming apparent that each dendritic cell subset is different in its capacity to induce and modulate specific types of immune responses; however, there is still a lack of resolution and deep understanding of dendritic cell subset functional specialization. This gap in knowledge is an impediment for the rational design of immune interventions. Our research program focuses on advancing our understanding of mouse and human dendritic cell subsets, revealing their endowed capacity to induce distinct types of immune responses, and designing novel strategies to exploit them for vaccines and therapies.

  • Debra M. Ikeda, M.D.

    Debra M. Ikeda, M.D.

    Professor of Radiology (Breast Imaging)

    Current Research and Scholarly Interests My research interests are quality improvement in mammography positioning, digital breast tomosynthesis (DBT) cancer detection and imaging pitfalls, MRI-guided breast biopsy, MRI BIRADS 3 lesions, fiducial markers for Radiation Therapy, correlation of breast cancer and FDG PET imaging, percutaneous breast biopsy

  • Gentaro Ikeda

    Gentaro Ikeda

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio My long-term goal is to become a physician scientist and develop innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on my experience as a cardiologist for the past 5 years, I have become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including ?-blockers, ivabradine, and renin?angiotensin?aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, I moved to academia to conduct translational research. During my graduate training in the Egashira Lab, I focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. I obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. I realized the importance of translational research and the great potential of DDS to overcome many clinical problems. I developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. I published a first author paper and received academic awards for my novel science. Since becoming a postdoctoral fellow in the Yang Lab, I have continued to build upon my previous training in translational research. I am currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for the failing heart.

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    Bio Program Director (U.S) Japan Biodesign, Stanford Biodesign
    Cardiovascular Medicine, Stanford University


    Dr. Ikeno is a Research Associate, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406

  • Jennifer Ikle

    Jennifer Ikle

    Instructor, Pediatrics - Endocrinology and Diabetes

    Current Research and Scholarly Interests Jen is interested in the genetic factors that lead to abnormal beta-cell function and insulin secretion, causing disorders such as hyperinsulinism and neonatal diabetes. Jen?s current research focus is the use of zebrafish models, combined with genetics and genomics, to understand cellular and molecular mechanisms of glucose metabolism and elucidate previously unknown players involved in the regulation of insulin secretion.

  • Daniel Imler

    Daniel Imler

    Clinical Associate Professor, Emergency Medicine

    Current Research and Scholarly Interests I am interested in understanding the impact of smart, agile clinical pathways to drive behavior change among providers.

  • Fatih Inci

    Fatih Inci

    Affiliate, Rad/Canary Center at Stanford for Cancer Early Detection

    Bio Dr. Fatih Inci is currently working as a Research Scientist at Stanford University School of Medicine, Canary Center at Stanford for Cancer Early Detection. He has been guiding and working with a group of researchers, including postdoctoral fellows, graduate, undergraduate, and high school students, who focus on micro- and nano-technologies for biomedical and bioengineering applications. Dr. Inci received his B.Sc. degree at the Department of Molecular Biology and Genetics in 2007 with magna cum laude honor from Istanbul University (Turkey), and also studied as an Sokrates student at the Department of Biology in University of Groningen (Netherlands) in 2005. He received his Ph.D. degree at the Department of Molecular Biology-Genetics & Biotechnology with summa cum laude honor from Istanbul Technical University (Turkey) in 2013. During his Ph.D. studies, he was also appointed as a visiting scientist at University of New South Wales (Sydney, Australia) and University of Technology Sydney (Australia), as well as working as a research scholar/trainee at Brigham and Women?s Hospital (BWH)-Harvard Medical School, and Harvard-MIT Health Sciences and Technology Division (Boston, MA). Upon the completion of his Ph.D. studies, Dr. Inci worked as a postdoctoral research fellow at BWH-Harvard Medical School (2013-2014) and Stanford University School of Medicine (2014-2015).

    Dr. Inci has published his research work in the most prestigious journals, including Proceedings of the National Academy of Sciences of the United States of America (PNAS), ACS Nano, Nature Scientific Reports, Nature Light: Science & Applications, Small, Lab on a chip, Advanced Science, Biomacromolecules, Advanced Drug Delivery Reviews, ACS Chemical Reviews, Biotechnology Advances, Annual Review of Medicine, Materials Today, Trends in Biotechnology. Besides his research publications, he has contributed to the publication of 7 book chapters (including 3 chapters in press) and 3 editorial/perspective papers. He is also editing 3 scientific books in the world's renowned publishers, i.e., Springer Press and World Scientific Publishing Company. His research findings have been presented in national and international conferences, ranging in geography from Barcelona to Osaka, Sydney to Boston, Rio de Janeiro to San Diego and Phoenix to San Francisco. Moreover, he has secured his research findings, technological developments, and scientific discoveries with 6 U.S. patents. Some of them have already been licensed by companies to produce commercial products in the United States, and distributed throughout the world. One such example is his patent in the field of forensics that has been translated into two viable commercial products (CSI-Q and NGDE) produced in the United States by DxNow, Inc.

    Dr. Inci?s qualified scientific work has been highlighted and recognized by well-renowned national and international organizations as well as government entities, including National Institute of Health, Nature Medicine, Science AAAS, Popular Science, Newsweek, Boston University, Canary Center-Stanford University, Brigham & Women?s Hospital, A*STAR, Center for Integration of Medicine and Innovative Technology (CIMIT), and Epilepsy Foundation. He has also been awarded with various scholarships and grants from European Molecular Biology Organization-European Science Foundation (EMBO-ESF), American Chemical Society, and Turkey Scientific and Technological Research Society (TUBITAK). He is a professional member at the world?s largest and most prestigious scientific societies, including the American Association for the Advancement of Science (AAAS), Royal Society of Chemistry (RSC), American Association for Cancer Research (AACR), and National Postdoctoral Association (NPA).

  • Erik Ingelsson

    Erik Ingelsson

    Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Health Research and Policy (Epidemiology)

    Current Research and Scholarly Interests We are interested in the link between metabolic disturbances, such as obesity and insulin resistance, and the development of cardiovascular disease. Our research is translational and interdisciplinary, combining population-based studies with molecular biology to reach new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel drug targets.

  • Alexander Ioannidis

    Alexander Ioannidis

    Postdoctoral Research Fellow, Biomedical Data Sciences

    Bio Alexander Ioannidis (PhD, MPhil) graduated summa cum laude from Harvard University in Chemistry and Physics and earned an M.Phil in Computational Biology and Diploma in Greek from the University of Cambridge. His Ph.D. from Stanford University was in Computational and Mathematical Engineering, where he teaches machine learning and data science. He also has an M.S. in Mgmt. Sci. and Eng. (Optimization) from Stanford. Prior to Stanford, he worked in superconducting computing logic and quantum computing at Northrop Grumman. As a current research fellow in the Stanford School of Medicine (Department of Biomedical Data Science), his work focuses on applying computational methods to problems in genomics and population genetics.

    ---------------------------------------

    I work on novel algorithm design (particularly ancestry related) for several large-scale genomic studies that aim at understanding genetic causes of disease.

    I also focus on projects at the intersection of history and population genetics, including work with native communities. As the grandson of Cappadocian refugees expelled from their native land, I try to engage with the complex sentiments of displaced indigenous peoples in these projects. Pain over the disruption of community heritage and over dispossession from traditional sites often remains raw. If engagement with descendant communities is lacking, research into our past can often feel like a continuation, even a legitimation, of dispossession. Combined alongside a dialogue with native communities, however, genetics can play a small role in helping to reclaim ancestral stories and dispersed ancestral connections. I hope our work in this area plays a constructive role in that process.

    As written by the poet Rumi in the language of the Cappadocians (Rűm),
    ???? ??? ???????? ???? ?? ?????
    ?Tell me what happened to you, tell me what you have lost.?
    [Rumi; Konya ms 67; translit. ?? ?? ?? ??????, ?? ?? ?? ??????]

  • John P.A. Ioannidis

    John P.A. Ioannidis

    C. F. Rehnborg Professor in Disease Prevention in the School of Medicine, Professor of Medicine, of Health Research and Policy (Epidemiology) and by courtesy, of Statistics and of Biomedical Data Science

    Current Research and Scholarly Interests Meta-research
    Evidence-based medicine
    Clinical and molecular epidemiology
    Human genome epidemiology
    Research design
    Reporting of research
    Empirical evaluation of bias in research
    Randomized trials
    Statistical methods and modeling
    Meta-analysis and large-scale evidence
    Prognosis, predictive, personalized, precision medicine and health
    Sociology of science

  • Cristiana Iosef

    Cristiana Iosef

    Basic Life Science Research Scientist, Cardiothoracic Surgery

    Bio Dr. Cristiana Iosef returned to Stanford University Medical School in Feb 2019, after serving for five years, as a research associate professor of Pharmacology, in the Nevada State University. Enthusiastically, Cristiana joined Dr Michael Fischbein?s research program in the Department of Cardiothoracic Surgery, and she will focus on the molecular cues leading to vascular aneurysms. The long-term goal is to design high precision personalized therapies based on induced pluripotent stem cells (iPSC) aimed to restore the defective signaling pathways associated with cardio-vascular pathologies, or to predict their evolution. This collaboration started in 2010 while being a member of the Stanford/Pediatrics Department (Alvira lab) and yielded an important publication: Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP. miR-29b participates in early aneurysm development in Marfan syndrome. Circ Res. 2012 Jan 20;110(2):312-24. Dr Iosef is a dvm-surgeon and molecular signaling expert and she began her research career as a Fulbright Graduate Scholar in Washington University School of Medicine (St Louis, MO). She continued to specialize in animal models for human medicine practice in the Ohio State University. Prior to joining Stanford University in 2010, Cristiana developed an important body of work on signal-transduction and proteomic profiling of placental mesenchymal stem cells, in the University of Western Ontario, Canada (2001-10). In addition to her academic duties, Cristiana served as an associate director of the Mountain West Clinical Translational Research Consortium (2016-19). When she is not in the lab, Dr Iosef can be found hiking on the Pacific coast, skiing in the Sierras, visiting art galleries or she may study for her brown-belt exam in martial arts at JKA Shotokan Stanford. Aside from being a devoted vet-surgeon scientist, Cristiana is the proud mom of a young corporate lawyer.

  • Eric Ip

    Eric Ip

    Clinical Associate Professor, Medicine - Primary Care and Population Health

    Current Research and Scholarly Interests My research interests include the use and abuse of anabolic steroids and other performance enhancing/cognitive enhacing drugs.

  • Cynthia Irvine

    Cynthia Irvine

    Associate Dean, Office of Medical Education, School of Medicine - Student Affairs

    Current Role at Stanford Associate Dean, Office of Medical Education (MD Program); Co-Director, Scholarly Concentration in Medical Education

Footer Links:

Stanford Medicine Resources: